source
- Merck and Moderna’s personalized mRNA vaccine shows longer recurrence-free survival in phase 3 melanoma trialMerck and Moderna reported that their individualized mRNA cancer vaccine, given together with Keytruda, extended the time patients remained free of melanoma recurrence in a late-stage study. The p…
- FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vaxStrain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.